Investors. Presentations. There are no presentations available at this time. Shareholder Tools. Print Page. Email Alerts · RSS Feeds · Investor Contact.
Press Releases ; March 28, 2024. AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights.
Investor Relations. Company Overview. Avalo (AVTX) is a clinical stage ... Avalo Reports 2023 Financial Results and Provides Business Updates. Mar 27, 2024 • 4 ...
Missing: antx | Show results with:antx
(Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet ...
This information can be used by investors to verify and understand the financial position of the company. Many, but not all SEC filings are available in the ...
According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.61. The reported EPS for the same ...
Find the latest AN2 Therapeutics, Inc. (ANTX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Missing: relations | Show results with:relations
Rating
(3,975)
AN2 Therapeutics, Inc. (ANTX) will release its next earnings report on May 8, 2024. In the last quarter AN2 Therapeutics, Inc. reported -$0.736 EPS in ...
Missing: relations | Show results with:relations
ANTX | Complete AN2 Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Missing: relations | Show results with:relations
AN2 Therapeutics, Inc. is currently listed on NASDAQ under ANTX. One share of ANTX stock can currently be purchased for approximately $2.38. Is AN2 Therapeutics ...